Indication

Mucopolysaccharidosis type IV-A

Mucopolysaccharidosis type IV-A, also known as Morquio A syndrome, is a rare, autosomal recessive lysosomal storage disease caused by pathogenic variants in the *GALNS* gene. Read more about Mucopolysaccharidosis type IV-A

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Mucopolysaccharidosis type IV-A therapies.

Showing 1–1 of 1 drugs

VIMIZIM (elosulfase alfa)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS·MUCOPOLYSACCHARIDOSIS TYPE IV-A
BIOMARIN PHARMA
Filter & compare in the drug finder →Opens the drug finder with Mucopolysaccharidosis type IV-A preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Mucopolysaccharidosis type IV-A.

Mucopolysaccharidosis type IV-A, also known as Morquio A syndrome, is a rare, autosomal recessive lysosomal storage disease caused by pathogenic variants in the *GALNS* gene.

This genetic defect results in a deficiency of the enzyme N-acetylgalactosamine-6-sulfate sulfatase, leading to the progressive accumulation of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate predominantly in bone, cartilage, and connective tissues.

The condition primarily impacts the pediatric-onset skeletal system and manifests as severe systemic skeletal dysplasia, including marked short stature with a disproportionately short trunk, kyphoscoliosis, chest deformities, joint hypermobility, and life-threatening atlantoaxial instability with cervical myelopathy.

Additional non-skeletal complications often involve corneal clouding, sensorineural or conductive hearing loss, restrictive pulmonary disease, and cardiac valve dysfunction, typically in the absence of primary cognitive impairment.

Personalize your experience

Follow Mucopolysaccharidosis type IV-A and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it